Cloarec 1994.

Study characteristics
Methods	Study design: randomised, double‐blind, placebo‐controlled Method of randomisation: not stated Exclusions post randomisation: 16/120 (13%) Losses to follow‐up: not stated
Participants	Country: France Setting: not stated Number: 120 patients Age: mean 50 years Gender: not stated Inclusion criteria: history of CVI for several years Exclusion criteria: not stated
Interventions	Treatment: O‐(beta‐hydroxyethyl)‐rutoside 2000 mg per day Control: placebo Duration: 56 days Follow‐up: 56 days
Outcomes	Primary Reduction in calf and ankle circumference Secondary Pain Cramps Tiredness Swelling Restless legs Pitting oedema measured by a scale (0 to 3) Plethysmographic parameters Transcutaneous oxygen tension
Notes	This clinical trial is published in abstract format; not possible to extract data showing results
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "A multicenter double blind randomized clinical trial was designed" Comment: no methods described for randomisation of participants
Allocation concealment (selection bias)	Unclear risk	Comment: no information given about methods used for allocation concealment
Blinding (patients)	Unclear risk	Comment: no information given about methods used for blinding
Blinding (study researchers)	Unclear risk	Comment: no information given about methods used for blinding
Blinding (outcome assessment)	Unclear risk	Comment: no information given about methods used for blinding
Incomplete outcome data	Low risk	Comment: only 13% drop‐out rate (16/120) for violation of study protocol reported
Selective reporting	High risk	Comment: no protocol identified. In the methods section, subjective symptoms identified that were not reported in the results section (pain, heaviness, swelling, restless leg, cramps, presence of pitting oedema)
Other bias	Low risk	Comment: none detected